Randomized phase II study comparing the efficacy and safety of SOX versus mFOLFOX6 as neoadjuvant chemotherapy without radiotherapy for locally advanced rectal cancer (KSCC1301)

被引：0
|
作者：
Keisuke Miwa
Eiji Oki
Masanobu Enomoto
Keisuke Ihara
Koji Ando
Fumihiko Fujita
Masahiro Tominaga
Shinichiro Mori
Goro Nakayama
Mototsugu Shimokawa
Hiroshi Saeki
Hideo Baba
Masaki Mori
Yoshito Akagi
机构：
[1] Kurume University Hospital,Multidisciplinary Treatment Cancer Center
[2] Kyushu University,Department of Surgery and Science, Graduate School of Medical Sciences
[3] Tokyo Medical University,Gastrointestinal and Pediatric Surgery
[4] Dokkyo Medical University,First Department of Surgery
[5] Kurume University School of Medicine,Department of Surgery
[6] Department of Gastroenterological Surgery,Department of Digestive Surgery, Breast and Thyroid Surgery
[7] Hyogo Cancer Center,Department of Gastroenterological Surgery, Graduate School of Medicine
[8] Kagoshima University,Cancer Biostatistics Laboratory, Clinical Research Institute
[9] Nagoya University,Department of Biostatistics
[10] National Hospital Organization Kyusyu Cancer Center,Department of Gastroenterological Surgery
[11] Yamaguchi University Graduate School of Medicine,Department of Gastroenterological Surgery
[12] Gunma University Graduate School of Medicine,undefined
[13] Kumamoto University Graduate School of Medicine,undefined
来源：
BMC Cancer | / 21卷
关键词：
Rectal cancer; Neoadjuvant chemotherapy; Chemoradiotherapy; SOX; mFOLFOX6;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [41] A phase II study of neoadjuvant bevacizumab plus capecitabine and concomitant radiotherapy in patients with locally advanced rectal cancer
    Giampietro Gasparini
    Francesco Torino
    Takayuki Ueno
    Stefano Cascinu
    Teresa Troiani
    Alberto Ballestrero
    Rossana Berardi
    Junichi Shishido
    Akihiko Yoshizawa
    Yukiko Mori
    Satoshi Nagayama
    Paola Morosini
    Masakazu Toi
    Angiogenesis, 2012, 15 : 141 - 150
  • [42] Efficacy and Safety of Apatinib plus Neoadjuvant Chemotherapy for Locally Advanced Esophageal Squamous Cancer: A Phase II Trial
    Yang, Bo
    Guo, Xiaofeng
    Le, Cheng
    Su, Wenzhong
    Li, Xiaoming
    Zhang, Yanfeng
    Yang, Guangyi
    Liang, Weimin
    Zheng, Zhixin
    Wu, Junpeng
    Zhang, Yaowen
    Hao, Anlin
    BIOMED RESEARCH INTERNATIONAL, 2022, 2022
  • [43] A phase II study of cetuximab, capecitabine and radiotherapy in neoadjuvant treatment of patients with locally advanced resectable rectal cancer
    Velenik, V.
    Ocvirk, J.
    Oblak, I.
    Anderluh, F.
    EJSO, 2010, 36 (03): : 244 - 250
  • [44] A phase II study of neoadjuvant bevacizumab plus capecitabine and concomitant radiotherapy in patients with locally advanced rectal cancer
    Gasparini, Giampietro
    Torino, Francesco
    Ueno, Takayuki
    Cascinu, Stefano
    Troiani, Teresa
    Ballestrero, Alberto
    Berardi, Rossana
    Shishido, Junichi
    Yoshizawa, Akihiko
    Mori, Yukiko
    Nagayama, Satoshi
    Morosini, Paola
    Toi, Masakazu
    ANGIOGENESIS, 2012, 15 (01) : 141 - 150
  • [45] Efficacy and Feasibility of Adding Induction Chemotherapy to Neoadjuvant Chemoradiation in Locally Advanced Rectal Cancer: A Phase II Clinical Trial
    Nasrolahi, Hamid
    Mirzaei, Sepideh
    Mohammadianpanah, Mohammad
    Bananzadeh, Ali Mohammad
    Mokhtari, Maral
    Sasani, Mohammad Reza
    Mosalaei, Ahmad
    Omidvari, Shapour
    Ansari, Mansour
    Ahmadloo, Niloofar
    Hamedi, Seyed Hasan
    Khanjani, Nezhat
    ANNALS OF COLOPROCTOLOGY, 2019, 35 (05) : 242 - 248
  • [46] A phase II study to evaluate safety and efficacy of neoadjuvant pembrolizumab and radiotherapy in localized MSS rectal cancer
    Kossler, Thibaud
    Nicolas, Buchs
    Dutoit, Valerie
    Puppa, Giacomo
    Tsantoulis, Petros
    Frossard, Jean-Louis
    Bichard, Philippe
    Montet, Xavier
    Mckee, Thomas
    Di Marco, Mariagrazia
    Dietrich, Pierre-Yves
    Roth, Arnaud
    Zilli, Thomas
    Ris, Frederic
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [47] A Prospective Multicenter Phase II Study on the Feasibility and Efficacy of S-1 and Oxaliplatin Neoadjuvant Chemotherapy for Locally Advanced Rectal Cancer
    Sakamoto, Yoshiyuki
    Morohashi, Hajime
    Miura, Takuya
    Tsutsumi, Shinji
    Takahashi, Seiji
    Hirama, Kimiaki
    Wakiya, Taiichi
    Hakamada, Kenichi
    DISEASES OF THE COLON & RECTUM, 2022, 65 (05) : 663 - 671
  • [48] Cediranib With mFOLFOX6 Versus Bevacizumab With mFOLFOX6 As First-Line Treatment for Patients With Advanced Colorectal Cancer: A Double-Blind, Randomized Phase III Study (HORIZON III)
    Schmoll, Hans-Joachim
    Cunningham, David
    Sobrero, Alberto
    Karapetis, Christos S.
    Rougier, Philippe
    Koski, Sheryl L.
    Kocakova, Ilona
    Bondarenko, Igor
    Bodoky, Gyoergy
    Mainwaring, Paul
    Salazar, Ramon
    Barker, Peter
    Mookerjee, Bijoyesh
    Robertson, Jane
    Van Cutsem, Eric
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (29) : 3588 - 3595
  • [49] EFFICACY AND SAFETY OF TWO NEOADJUVANT STRATEGIES WITH BEVACIZUMAB IN LOCALLY ADVANCED RESECTABLE RECTAL CANCER: INTERIM RESULTS OF A RANDOMIZED, NON-COMPARATIVE PHASE II STUDY
    Bosset, J.
    Mantion, G.
    Andre, T.
    Boudghene, F.
    Piard, F.
    Mornex, F.
    Maingon, P.
    Adenis, A.
    Piutti, M.
    Borg, C.
    ANNALS OF ONCOLOGY, 2012, 23 : 206 - 206
  • [50] mFOLFOX6 versus mFOLFOX6 D aflibercept as neoadjuvant treatment in MRI-defined T3-rectal cancer: a randomized phase-II-trial of the German Rectal Cancer Study Group (CAO/ARO/AIO 0214) and the ABCSG (R-06) (vol 9, 103703, 2024)
    Hofheinz, R. -D.
    Herrle, F.
    Dechow, T.
    von Weikersthal, L. F.
    Welslau, M.
    Lettmaier, S.
    Burkart, C.
    Kubicka, S.
    Kochen, L.
    Merx, K.
    Krause, K.
    Ebert, M.
    Roedel, C.
    Fokas, E.
    Ghadimi, M.
    Reissfelder, C.
    Gaiser, T.
    ESMO OPEN, 2025, 10 (02)
12345